thiotepa

P2, N=113, Active, not recruiting, Alliance for Clinical Trials in Oncology

P2, N=195, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting

P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=58, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | N=20 --> 58

P1, N=60, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Nov 2027

P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030

P2, N=37, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

P2, N=26, Recruiting, The First Affiliated Hospital with Nanjing Medical University

These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies.

P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital

Treatment with intrathecal pemetrexed via the Ommaya reservoir, combined with intravenous tislelizumab and carboplatin, resulted in 12 months of progression-free survival. For subsequent central nervous system progression involving both brain parenchymal metastasis and LM, we administered whole brain radiotherapy followed by second-line intrathecal thiotepa via Ommaya reservoir alongside tislelizumab and bevacizumab...Remarkably, the patient has survived nearly 29 months while maintaining good performance status and quality of life - to our knowledge, one of the longest reported survival for an NSCLC patient with LM harboring KRAS-G12V or other non-targetable mutations. This case suggests that combining ventriculoperitoneal shunt with Ommaya reservoir-delivered intrathecal chemotherapy may represent an effective therapeutic approach for LM patients.